The pre-conference meetings are not an integral part of the AMR Conference. However, when registering for the conference, you can indicate your interest to participate. The organizers will inform you about the acceptance of your participation shortly before the conference.
09:30 – 15:30
Workshop – Phage Therapy: What’s New and What’s Next?
This interactive workshop aims to delve into the development of a sustainable phage therapy value chain, emphasizing the progress, challenges and opportunities in phage therapy. Sessions will be held on scientific developments, clinical research, and phage manufacturing. Participants will also explore intellectual property strategies and engage in discussions about the global regulatory landscape. In addition, the event will include start-up showcases and an investor panel to discuss funding options and investment strategies. The workshop provides a platform for experts, entrepreneurs, and investors to explore the future of phage therapy. Number of participants will be limited.
Organized by
Fully booked
16:00 – 18:00
Networking meeting
Organized by
Fully booked
Conference Day 1
Tuesday, 25 February 2025 | Congress Center 2nd floor
08:45 – 10:30
BEAM Alliance General Assembly
open only to members of the BEAM Alliance
09:00 – 10:30
Pre-conference workshop
Title tbd
Jointly organized by
Moderator: Ursula Theuretzbacher (Center for Anti-Infective Agents)
Speakers: Malcolm Page (Antibiotic Research): “Integrating TPPs and TCPs in discovery strategies” Kenneth Bradley (F. Hoffmann-La Roche Ltd.): “Data driven decision making in antibiotics preclinical research”
11:00 – 12:00
Opening plenary
Taking action after renewed political commitment
12:00 – 13:30
Lunch break
13:30 – 14:30
Plenary session
Translating AMR clinical needs from local to global
15:00 – 16:00
Parallel sessions
I
Technology corner in diagnostics
II
Remarkable advances in AMR science
III
Pathogen reduction approaches to prevent AMR
16:30 – 17:30
Parallel sessions
I
Financing product development
II
PK/PD approaches to improve the translation of doses to clinic
III
Developing biologics for global purposes
18:00 – 19:30
Start-up pitch
Hosted by
10’000 € award sponsored by
Moderator: Douglas Häggström (INCATE)
Running order of pitching companies:
TabriX (presented by Marc Creus)
BrIgID Biologics (presented by Soumya Palliyil)
BamA Inhibitor (presented by Till Schäberle)
Microplate Dx (presented by Stuart Hannah)
Omnicin Therapeutics (presented by Auke van Heel)
Obulytix (presented by Yves Briers)
Tolka AI Therapeutics (presented by Johan Wikstrom)